Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorDEVILLIER, P.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMOLIMARD, Mathieu
dc.contributor.authorANSOLABEHERE, X.
dc.contributor.authorBARDOULAT, I.
dc.contributor.authorCOULOMBEL, N.
dc.contributor.authorMAUREL, F.
dc.contributor.authorLE JEUNNE, P.
dc.contributor.authorDEMOLY, P.
dc.date.accessioned2020-06-05T09:32:45Z
dc.date.available2020-06-05T09:32:45Z
dc.date.issued2019-07
dc.identifier.issn0105-4538en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/7760
dc.description.abstractEnBACKGROUND: Moderate-to-severe allergic rhinitis (AR) may increase the risk of developing or worsening asthma, whereas treatment of AR with subcutaneously or sublingual allergen immunotherapy (SLIT) may slow this progression. METHODS: In a retrospective real-world analysis, prescription fulfilment data were gathered from French retail pharmacies between 1 March 2012 and 31 December 2016. Using linear regression analyses, patients having received at least two prescriptions of grass pollen SLIT tablets over at least 2 successive years were compared with control patients having received symptomatic medications only. RESULTS: A total of 1099 SLIT patients and 27 475 control patients were included in the main analysis. With regard to symptomatic AR medication dispensing, we observed a 50% decrease in the pre-index/follow-up ratio in the SLIT group, a 30% increase in the control group without age matching (P < 0.0001 vs SLIT) and a 20% increase in the control group with age matching (P < 0.0001 vs SLIT). During the follow-up, 11 (1.8%) and 782 (5.3%) patients initiated asthma treatment in the SLIT and control groups, respectively. The relative risk of medication dispensing for new asthma was lower in the SLIT group (by 62.5% [29.1%-80.1%] without age matching (P = 0.0025) and by 63.7% [31.5%-80.7%] with age matching; P = 0.0018). SLIT was also associated with slower progression of asthma medication dispensing during the follow-up period, relative to the control group (regression coefficient: -0.58 [-0.74 to 0.42] without age matching (P < 0.0001) and -0.61 [-0.76 to -0.46] with age matching; P < 0.0001). CONCLUSION: Prescription of grass pollen SLIT tablets reduced the dispensing of AR and asthma medications in real life.
dc.language.isoENen_US
dc.subject.enPharmacoEpi-Drugs
dc.title.enImmunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: A retrospective database study in France
dc.title.alternativeAllergyen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/all.13705en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed30589088en_US
bordeaux.journalAllergyen_US
bordeaux.page1317-1326en_US
bordeaux.volume74en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue7en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Allergy&amp;rft.date=2019-07&amp;rft.volume=74&amp;rft.issue=7&amp;rft.spage=1317-1326&amp;rft.epage=1317-1326&amp;rft.eissn=0105-4538&amp;rft.issn=0105-4538&amp;rft.au=DEVILLIER,%20P.&amp;MOLIMARD,%20Mathieu&amp;ANSOLABEHERE,%20X.&amp;BARDOULAT,%20I.&amp;COULOMBEL,%20N.&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée